http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 16 Jun 2026 11:45:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Medincell+Reports+FY+2025-26+Annual+Results/26652628.html <p> <b>A year marked by solid execution, with</b> </p><ul class="bwlistdisc"> <li> <b>Continued UZEDY® ramp-up, supporting royalty growth</b> </li> <li> <b>Olanzapine LAI advancing into regulatory review ahead of its expected U.S. launch in Q4 2026 by Teva</b>1 </li> <li> <b>The first AbbVie program progressing toward the initiation of clinical development</b> </li> <li> <b>The expansion of both partnered and internal R&amp;D pipelines</b> </li> <li> <b>Continued strengthening of the technology platform</b> </li> </ul> <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Paris:MEDCL): </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td colspan="3" class="bwwidth11 bwsinglebottom" rowspan="1"><b>Key Financial Highlights</b></td> </tr> <tr> <td class="bwwidth11" rowspan="1" colspan="1" /> <td class="bwwidth1" rowspan="1" colspan="1" /> <td class="bwvertalignt bwpadl0 bwwidth88" rowspan="1" colspan="1"><p class="bwcellpmargin">   </p> </td> </tr> <tr> <td class="bwwidth11 bwvertalignt bwalignl" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignl"> <b>Total revenues</b> </p> </td> <td class="bwwidth1" rowspan="1" colspan="1" /> <td class="bwvertalignt bwpadl0 bwwidth88 bwalignl" rowspan="1" http://www.streetinsider.com/Press+Releases/Medincell+Reports+FY+2025-26+Annual+Results/26652628.html Tue, 16 Jun 2026 11:45:00 -0400 MEDCL O.01384798 http://www.streetinsider.com/Press+Releases/Medincell+Reports+FY+2025-26+Annual+Results/26652628.html <p> <b>A year marked by solid execution, with</b> </p><ul class="bwlistdisc"> <li> <b>Continued UZEDY® ramp-up, supporting royalty growth</b> </li> <li> <b>Olanzapine LAI advancing into regulatory review ahead of its expected U.S. launch in Q4 2026 by Teva</b>1 </li> <li> <b>The first AbbVie program progressing toward the initiation of clinical development</b> </li> <li> <b>The expansion of both partnered and internal R&amp;D pipelines</b> </li> <li> <b>Continued strengthening of the technology platform</b> </li> </ul> <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Paris:MEDCL): </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td colspan="3" class="bwwidth11 bwsinglebottom" rowspan="1"><b>Key Financial Highlights</b></td> </tr> <tr> <td class="bwwidth11" rowspan="1" colspan="1" /> <td class="bwwidth1" rowspan="1" colspan="1" /> <td class="bwvertalignt bwpadl0 bwwidth88" rowspan="1" colspan="1"><p class="bwcellpmargin">   </p> </td> </tr> <tr> <td class="bwwidth11 bwvertalignt bwalignl" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignl"> <b>Total revenues</b> </p> </td> <td class="bwwidth1" rowspan="1" colspan="1" /> <td class="bwvertalignt bwpadl0 bwwidth88 bwalignl" rowspan="1" http://www.streetinsider.com/Press+Releases/Medincell+Reports+FY+2025-26+Annual+Results/26652628.html Tue, 16 Jun 2026 11:45:00 -0400 MEDCL O.01384798 http://www.streetinsider.com/Business+Wire/Medincell+Reports+FY+2025-26+Annual+Results/26652628.html <p> <b>A year marked by solid execution, with</b> </p><ul class="bwlistdisc"> <li> <b>Continued UZEDY® ramp-up, supporting royalty growth</b> </li> <li> <b>Olanzapine LAI advancing into regulatory review ahead of its expected U.S. launch in Q4 2026 by Teva</b>1 </li> <li> <b>The first AbbVie program progressing toward the initiation of clinical development</b> </li> <li> <b>The expansion of both partnered and internal R&amp;D pipelines</b> </li> <li> <b>Continued strengthening of the technology platform</b> </li> </ul> <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Paris:MEDCL): </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td colspan="3" class="bwwidth11 bwsinglebottom" rowspan="1"><b>Key Financial Highlights</b></td> </tr> <tr> <td class="bwwidth11" rowspan="1" colspan="1" /> <td class="bwwidth1" rowspan="1" colspan="1" /> <td class="bwvertalignt bwpadl0 bwwidth88" rowspan="1" colspan="1"><p class="bwcellpmargin">   </p> </td> </tr> <tr> <td class="bwwidth11 bwvertalignt bwalignl" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignl"> <b>Total revenues</b> </p> </td> <td class="bwwidth1" rowspan="1" colspan="1" /> <td class="bwvertalignt bwpadl0 bwwidth88 bwalignl" rowspan="1" http://www.streetinsider.com/Business+Wire/Medincell+Reports+FY+2025-26+Annual+Results/26652628.html Tue, 16 Jun 2026 11:45:00 -0400 MEDCL O.01384798 http://www.streetinsider.com/Business+Wire/Medincell+Reports+FY+2025-26+Annual+Results/26652628.html <p> <b>A year marked by solid execution, with</b> </p><ul class="bwlistdisc"> <li> <b>Continued UZEDY® ramp-up, supporting royalty growth</b> </li> <li> <b>Olanzapine LAI advancing into regulatory review ahead of its expected U.S. launch in Q4 2026 by Teva</b>1 </li> <li> <b>The first AbbVie program progressing toward the initiation of clinical development</b> </li> <li> <b>The expansion of both partnered and internal R&amp;D pipelines</b> </li> <li> <b>Continued strengthening of the technology platform</b> </li> </ul> <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Paris:MEDCL): </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td colspan="3" class="bwwidth11 bwsinglebottom" rowspan="1"><b>Key Financial Highlights</b></td> </tr> <tr> <td class="bwwidth11" rowspan="1" colspan="1" /> <td class="bwwidth1" rowspan="1" colspan="1" /> <td class="bwvertalignt bwpadl0 bwwidth88" rowspan="1" colspan="1"><p class="bwcellpmargin">   </p> </td> </tr> <tr> <td class="bwwidth11 bwvertalignt bwalignl" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignl"> <b>Total revenues</b> </p> </td> <td class="bwwidth1" rowspan="1" colspan="1" /> <td class="bwvertalignt bwpadl0 bwwidth88 bwalignl" rowspan="1" http://www.streetinsider.com/Business+Wire/Medincell+Reports+FY+2025-26+Annual+Results/26652628.html Tue, 16 Jun 2026 11:45:00 -0400 MEDCL O.01384798 http://www.streetinsider.com/Press+Releases/Medincell%3A+Videoconference+and+Publication+of+Annual+Financial+Results%2C+Tuesday%2C+June+16%2C+2026/26564027.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting of live videoconference on Tuesday, June 16, 2026, to present its financial results for the fiscal year ending March 31, 2026. The results will be published earlier that day following the closing of the Paris stock exchange. </p><p> The presentation will be conducted simultaneously in English and French to accommodate a broad audience of investors, analysts, and stakeholders. </p><p> <b>Videoconference in English, 6:00pm CEST / 12:00pm ET <br /></b>&gt;<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.medincell.com%2Fannual-results-2025-2026-register%2F&amp;esheet=54543556&amp;newsitemid=20260528371317&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.medincell.com%2Fannual-results-2025-2026-register%2F&amp;index=1&amp;md5=b2c9e354ff5172db887b2e4dc580ae3b" shape="rect">https://www.medincell.com/annual-results-2025-2026-register/</a> </p><p> <b>Videoconference in French, 6:00pm CEST / 12:00pm http://www.streetinsider.com/Press+Releases/Medincell%3A+Videoconference+and+Publication+of+Annual+Financial+Results%2C+Tuesday%2C+June+16%2C+2026/26564027.html Thu, 28 May 2026 12:00:00 -0400 A.26800952 A.27499954 MEDCL O.00401804 O.00711722 O.01384798 http://www.streetinsider.com/Press+Releases/Medincell%3A+Videoconference+and+Publication+of+Annual+Financial+Results%2C+Tuesday%2C+June+16%2C+2026/26564027.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting of live videoconference on Tuesday, June 16, 2026, to present its financial results for the fiscal year ending March 31, 2026. The results will be published earlier that day following the closing of the Paris stock exchange. </p><p> The presentation will be conducted simultaneously in English and French to accommodate a broad audience of investors, analysts, and stakeholders. </p><p> <b>Videoconference in English, 6:00pm CEST / 12:00pm ET <br /></b>&gt;<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.medincell.com%2Fannual-results-2025-2026-register%2F&amp;esheet=54543556&amp;newsitemid=20260528371317&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.medincell.com%2Fannual-results-2025-2026-register%2F&amp;index=1&amp;md5=b2c9e354ff5172db887b2e4dc580ae3b" shape="rect">https://www.medincell.com/annual-results-2025-2026-register/</a> </p><p> <b>Videoconference in French, 6:00pm CEST / 12:00pm http://www.streetinsider.com/Press+Releases/Medincell%3A+Videoconference+and+Publication+of+Annual+Financial+Results%2C+Tuesday%2C+June+16%2C+2026/26564027.html Thu, 28 May 2026 12:00:00 -0400 A.26800952 A.27499954 MEDCL O.00401804 O.00711722 O.01384798 http://www.streetinsider.com/Press+Releases/Medincell%3A+Videoconference+and+Publication+of+Annual+Financial+Results%2C+Tuesday%2C+June+16%2C+2026/26564027.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting of live videoconference on Tuesday, June 16, 2026, to present its financial results for the fiscal year ending March 31, 2026. The results will be published earlier that day following the closing of the Paris stock exchange. </p><p> The presentation will be conducted simultaneously in English and French to accommodate a broad audience of investors, analysts, and stakeholders. </p><p> <b>Videoconference in English, 6:00pm CEST / 12:00pm ET <br /></b>&gt;<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.medincell.com%2Fannual-results-2025-2026-register%2F&amp;esheet=54543556&amp;newsitemid=20260528371317&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.medincell.com%2Fannual-results-2025-2026-register%2F&amp;index=1&amp;md5=b2c9e354ff5172db887b2e4dc580ae3b" shape="rect">https://www.medincell.com/annual-results-2025-2026-register/</a> </p><p> <b>Videoconference in French, 6:00pm CEST / 12:00pm http://www.streetinsider.com/Press+Releases/Medincell%3A+Videoconference+and+Publication+of+Annual+Financial+Results%2C+Tuesday%2C+June+16%2C+2026/26564027.html Thu, 28 May 2026 12:00:00 -0400 A.26800952 A.27499954 MEDCL O.00401804 O.00711722 O.01384798 http://www.streetinsider.com/Press+Releases/Medincell%3A+Videoconference+and+Publication+of+Annual+Financial+Results%2C+Tuesday%2C+June+16%2C+2026/26564027.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting of live videoconference on Tuesday, June 16, 2026, to present its financial results for the fiscal year ending March 31, 2026. The results will be published earlier that day following the closing of the Paris stock exchange. </p><p> The presentation will be conducted simultaneously in English and French to accommodate a broad audience of investors, analysts, and stakeholders. </p><p> <b>Videoconference in English, 6:00pm CEST / 12:00pm ET <br /></b>&gt;<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.medincell.com%2Fannual-results-2025-2026-register%2F&amp;esheet=54543556&amp;newsitemid=20260528371317&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.medincell.com%2Fannual-results-2025-2026-register%2F&amp;index=1&amp;md5=b2c9e354ff5172db887b2e4dc580ae3b" shape="rect">https://www.medincell.com/annual-results-2025-2026-register/</a> </p><p> <b>Videoconference in French, 6:00pm CEST / 12:00pm http://www.streetinsider.com/Press+Releases/Medincell%3A+Videoconference+and+Publication+of+Annual+Financial+Results%2C+Tuesday%2C+June+16%2C+2026/26564027.html Thu, 28 May 2026 12:00:00 -0400 A.26800952 A.27499954 MEDCL O.00401804 O.00711722 O.01384798 http://www.streetinsider.com/Press+Releases/Medincell%3A+Videoconference+and+Publication+of+Annual+Financial+Results%2C+Tuesday%2C+June+16%2C+2026/26564027.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting of live videoconference on Tuesday, June 16, 2026, to present its financial results for the fiscal year ending March 31, 2026. The results will be published earlier that day following the closing of the Paris stock exchange. </p><p> The presentation will be conducted simultaneously in English and French to accommodate a broad audience of investors, analysts, and stakeholders. </p><p> <b>Videoconference in English, 6:00pm CEST / 12:00pm ET <br /></b>&gt;<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.medincell.com%2Fannual-results-2025-2026-register%2F&amp;esheet=54543556&amp;newsitemid=20260528371317&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.medincell.com%2Fannual-results-2025-2026-register%2F&amp;index=1&amp;md5=b2c9e354ff5172db887b2e4dc580ae3b" shape="rect">https://www.medincell.com/annual-results-2025-2026-register/</a> </p><p> <b>Videoconference in French, 6:00pm CEST / 12:00pm http://www.streetinsider.com/Press+Releases/Medincell%3A+Videoconference+and+Publication+of+Annual+Financial+Results%2C+Tuesday%2C+June+16%2C+2026/26564027.html Thu, 28 May 2026 12:00:00 -0400 A.26800952 A.27499954 MEDCL O.00401804 O.00711722 O.01384798 http://www.streetinsider.com/Press+Releases/Medincell%3A+Videoconference+and+Publication+of+Annual+Financial+Results%2C+Tuesday%2C+June+16%2C+2026/26564027.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting of live videoconference on Tuesday, June 16, 2026, to present its financial results for the fiscal year ending March 31, 2026. The results will be published earlier that day following the closing of the Paris stock exchange. </p><p> The presentation will be conducted simultaneously in English and French to accommodate a broad audience of investors, analysts, and stakeholders. </p><p> <b>Videoconference in English, 6:00pm CEST / 12:00pm ET <br /></b>&gt;<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.medincell.com%2Fannual-results-2025-2026-register%2F&amp;esheet=54543556&amp;newsitemid=20260528371317&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.medincell.com%2Fannual-results-2025-2026-register%2F&amp;index=1&amp;md5=b2c9e354ff5172db887b2e4dc580ae3b" shape="rect">https://www.medincell.com/annual-results-2025-2026-register/</a> </p><p> <b>Videoconference in French, 6:00pm CEST / 12:00pm http://www.streetinsider.com/Press+Releases/Medincell%3A+Videoconference+and+Publication+of+Annual+Financial+Results%2C+Tuesday%2C+June+16%2C+2026/26564027.html Thu, 28 May 2026 12:00:00 -0400 A.26800952 A.27499954 MEDCL O.00401804 O.00711722 O.01384798 http://www.streetinsider.com/Business+Wire/Medincell%3A+Videoconference+and+Publication+of+Annual+Financial+Results%2C+Tuesday%2C+June+16%2C+2026/26564027.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting of live videoconference on Tuesday, June 16, 2026, to present its financial results for the fiscal year ending March 31, 2026. The results will be published earlier that day following the closing of the Paris stock exchange. </p><p> The presentation will be conducted simultaneously in English and French to accommodate a broad audience of investors, analysts, and stakeholders. </p><p> <b>Videoconference in English, 6:00pm CEST / 12:00pm ET <br /></b>&gt;<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.medincell.com%2Fannual-results-2025-2026-register%2F&amp;esheet=54543556&amp;newsitemid=20260528371317&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.medincell.com%2Fannual-results-2025-2026-register%2F&amp;index=1&amp;md5=b2c9e354ff5172db887b2e4dc580ae3b" shape="rect">https://www.medincell.com/annual-results-2025-2026-register/</a> </p><p> <b>Videoconference in French, 6:00pm CEST / 12:00pm http://www.streetinsider.com/Business+Wire/Medincell%3A+Videoconference+and+Publication+of+Annual+Financial+Results%2C+Tuesday%2C+June+16%2C+2026/26564027.html Thu, 28 May 2026 12:00:00 -0400 A.26800952 A.27499954 MEDCL O.00401804 O.00711722 O.01384798 http://www.streetinsider.com/Business+Wire/Medincell%3A+Videoconference+and+Publication+of+Annual+Financial+Results%2C+Tuesday%2C+June+16%2C+2026/26564027.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting of live videoconference on Tuesday, June 16, 2026, to present its financial results for the fiscal year ending March 31, 2026. The results will be published earlier that day following the closing of the Paris stock exchange. </p><p> The presentation will be conducted simultaneously in English and French to accommodate a broad audience of investors, analysts, and stakeholders. </p><p> <b>Videoconference in English, 6:00pm CEST / 12:00pm ET <br /></b>&gt;<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.medincell.com%2Fannual-results-2025-2026-register%2F&amp;esheet=54543556&amp;newsitemid=20260528371317&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.medincell.com%2Fannual-results-2025-2026-register%2F&amp;index=1&amp;md5=b2c9e354ff5172db887b2e4dc580ae3b" shape="rect">https://www.medincell.com/annual-results-2025-2026-register/</a> </p><p> <b>Videoconference in French, 6:00pm CEST / 12:00pm http://www.streetinsider.com/Business+Wire/Medincell%3A+Videoconference+and+Publication+of+Annual+Financial+Results%2C+Tuesday%2C+June+16%2C+2026/26564027.html Thu, 28 May 2026 12:00:00 -0400 A.26800952 A.27499954 MEDCL O.00401804 O.00711722 O.01384798 http://www.streetinsider.com/Business+Wire/Medincell%3A+Videoconference+and+Publication+of+Annual+Financial+Results%2C+Tuesday%2C+June+16%2C+2026/26564027.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting of live videoconference on Tuesday, June 16, 2026, to present its financial results for the fiscal year ending March 31, 2026. The results will be published earlier that day following the closing of the Paris stock exchange. </p><p> The presentation will be conducted simultaneously in English and French to accommodate a broad audience of investors, analysts, and stakeholders. </p><p> <b>Videoconference in English, 6:00pm CEST / 12:00pm ET <br /></b>&gt;<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.medincell.com%2Fannual-results-2025-2026-register%2F&amp;esheet=54543556&amp;newsitemid=20260528371317&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.medincell.com%2Fannual-results-2025-2026-register%2F&amp;index=1&amp;md5=b2c9e354ff5172db887b2e4dc580ae3b" shape="rect">https://www.medincell.com/annual-results-2025-2026-register/</a> </p><p> <b>Videoconference in French, 6:00pm CEST / 12:00pm http://www.streetinsider.com/Business+Wire/Medincell%3A+Videoconference+and+Publication+of+Annual+Financial+Results%2C+Tuesday%2C+June+16%2C+2026/26564027.html Thu, 28 May 2026 12:00:00 -0400 A.26800952 A.27499954 MEDCL O.00401804 O.00711722 O.01384798 http://www.streetinsider.com/Business+Wire/Medincell%3A+Videoconference+and+Publication+of+Annual+Financial+Results%2C+Tuesday%2C+June+16%2C+2026/26564027.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting of live videoconference on Tuesday, June 16, 2026, to present its financial results for the fiscal year ending March 31, 2026. The results will be published earlier that day following the closing of the Paris stock exchange. </p><p> The presentation will be conducted simultaneously in English and French to accommodate a broad audience of investors, analysts, and stakeholders. </p><p> <b>Videoconference in English, 6:00pm CEST / 12:00pm ET <br /></b>&gt;<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.medincell.com%2Fannual-results-2025-2026-register%2F&amp;esheet=54543556&amp;newsitemid=20260528371317&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.medincell.com%2Fannual-results-2025-2026-register%2F&amp;index=1&amp;md5=b2c9e354ff5172db887b2e4dc580ae3b" shape="rect">https://www.medincell.com/annual-results-2025-2026-register/</a> </p><p> <b>Videoconference in French, 6:00pm CEST / 12:00pm http://www.streetinsider.com/Business+Wire/Medincell%3A+Videoconference+and+Publication+of+Annual+Financial+Results%2C+Tuesday%2C+June+16%2C+2026/26564027.html Thu, 28 May 2026 12:00:00 -0400 A.26800952 A.27499954 MEDCL O.00401804 O.00711722 O.01384798 http://www.streetinsider.com/Business+Wire/Medincell%3A+Videoconference+and+Publication+of+Annual+Financial+Results%2C+Tuesday%2C+June+16%2C+2026/26564027.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting of live videoconference on Tuesday, June 16, 2026, to present its financial results for the fiscal year ending March 31, 2026. The results will be published earlier that day following the closing of the Paris stock exchange. </p><p> The presentation will be conducted simultaneously in English and French to accommodate a broad audience of investors, analysts, and stakeholders. </p><p> <b>Videoconference in English, 6:00pm CEST / 12:00pm ET <br /></b>&gt;<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.medincell.com%2Fannual-results-2025-2026-register%2F&amp;esheet=54543556&amp;newsitemid=20260528371317&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.medincell.com%2Fannual-results-2025-2026-register%2F&amp;index=1&amp;md5=b2c9e354ff5172db887b2e4dc580ae3b" shape="rect">https://www.medincell.com/annual-results-2025-2026-register/</a> </p><p> <b>Videoconference in French, 6:00pm CEST / 12:00pm http://www.streetinsider.com/Business+Wire/Medincell%3A+Videoconference+and+Publication+of+Annual+Financial+Results%2C+Tuesday%2C+June+16%2C+2026/26564027.html Thu, 28 May 2026 12:00:00 -0400 A.26800952 A.27499954 MEDCL O.00401804 O.00711722 O.01384798 http://www.streetinsider.com/Business+Wire/Medincell%3A+Videoconference+and+Publication+of+Annual+Financial+Results%2C+Tuesday%2C+June+16%2C+2026/26564027.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting of live videoconference on Tuesday, June 16, 2026, to present its financial results for the fiscal year ending March 31, 2026. The results will be published earlier that day following the closing of the Paris stock exchange. </p><p> The presentation will be conducted simultaneously in English and French to accommodate a broad audience of investors, analysts, and stakeholders. </p><p> <b>Videoconference in English, 6:00pm CEST / 12:00pm ET <br /></b>&gt;<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.medincell.com%2Fannual-results-2025-2026-register%2F&amp;esheet=54543556&amp;newsitemid=20260528371317&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.medincell.com%2Fannual-results-2025-2026-register%2F&amp;index=1&amp;md5=b2c9e354ff5172db887b2e4dc580ae3b" shape="rect">https://www.medincell.com/annual-results-2025-2026-register/</a> </p><p> <b>Videoconference in French, 6:00pm CEST / 12:00pm http://www.streetinsider.com/Business+Wire/Medincell%3A+Videoconference+and+Publication+of+Annual+Financial+Results%2C+Tuesday%2C+June+16%2C+2026/26564027.html Thu, 28 May 2026 12:00:00 -0400 A.26800952 A.27499954 MEDCL O.00401804 O.00711722 O.01384798 http://www.streetinsider.com/Press+Releases/Medincell+to+Participate+in+Jefferies+and+Evercore+Investor+Conferences+in+the+U.S.+in+June/26548312.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced that Christophe Douat, Chief Executive Officer, and Grace Kim, Chief Strategy Officer, U.S. Finance, will participate in the following leading U.S. investor conferences: </p><p> <b>Jefferies Annual NY Biotech Conference</b> </p><ul class="bwlistdisc"> <li> Dates: June 2-4, 2026 </li> <li> Location: New-York </li> <li> Presentation: 9:55 AM ET June 4, 2026 </li> <li> Live webcast and replay: <br /><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fevent.summitcast.com%2Fview%2FNgCqua4VVQjq9ibVWHVWca%2FBz7fjGhGyU3meEzqRduiXr&amp;esheet=54541710&amp;newsitemid=20260526323219&amp;lan=en-US&amp;anchor=https%3A%2F%2Fevent.summitcast.com%2Fview%2FNgCqua4VVQjq9ibVWHVWca%2FBz7fjGhGyU3meEzqRduiXr&amp;index=1&amp;md5=312723785633f98a004023774cc7e0d4" shape="rect">https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/Bz7fjGhGyU3meEzqRduiXr</a> </li> </ul><p> <b>Evercore Summer Symposium</b> </p><ul class="bwlistdisc"> <li> Dates: June 22-24, 2026 </li> <li> Location: Newport, Rhode Island </li> </ul><p> To schedule a meeting, please contact the conference organizers or reach out directly to Medincell. </p><p> <b>About Medincell</b> </p><p> Medincell is a clinical- and commercial-stage biopharmaceutical http://www.streetinsider.com/Press+Releases/Medincell+to+Participate+in+Jefferies+and+Evercore+Investor+Conferences+in+the+U.S.+in+June/26548312.html Tue, 26 May 2026 12:00:00 -0400 A.26800952 A.27499954 MEDCL O.00401804 O.00711722 O.01384798 http://www.streetinsider.com/Press+Releases/Medincell+to+Participate+in+Jefferies+and+Evercore+Investor+Conferences+in+the+U.S.+in+June/26548312.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced that Christophe Douat, Chief Executive Officer, and Grace Kim, Chief Strategy Officer, U.S. Finance, will participate in the following leading U.S. investor conferences: </p><p> <b>Jefferies Annual NY Biotech Conference</b> </p><ul class="bwlistdisc"> <li> Dates: June 2-4, 2026 </li> <li> Location: New-York </li> <li> Presentation: 9:55 AM ET June 4, 2026 </li> <li> Live webcast and replay: <br /><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fevent.summitcast.com%2Fview%2FNgCqua4VVQjq9ibVWHVWca%2FBz7fjGhGyU3meEzqRduiXr&amp;esheet=54541710&amp;newsitemid=20260526323219&amp;lan=en-US&amp;anchor=https%3A%2F%2Fevent.summitcast.com%2Fview%2FNgCqua4VVQjq9ibVWHVWca%2FBz7fjGhGyU3meEzqRduiXr&amp;index=1&amp;md5=312723785633f98a004023774cc7e0d4" shape="rect">https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/Bz7fjGhGyU3meEzqRduiXr</a> </li> </ul><p> <b>Evercore Summer Symposium</b> </p><ul class="bwlistdisc"> <li> Dates: June 22-24, 2026 </li> <li> Location: Newport, Rhode Island </li> </ul><p> To schedule a meeting, please contact the conference organizers or reach out directly to Medincell. </p><p> <b>About Medincell</b> </p><p> Medincell is a clinical- and commercial-stage biopharmaceutical http://www.streetinsider.com/Press+Releases/Medincell+to+Participate+in+Jefferies+and+Evercore+Investor+Conferences+in+the+U.S.+in+June/26548312.html Tue, 26 May 2026 12:00:00 -0400 A.26800952 A.27499954 MEDCL O.00401804 O.00711722 O.01384798 http://www.streetinsider.com/Press+Releases/Medincell+to+Participate+in+Jefferies+and+Evercore+Investor+Conferences+in+the+U.S.+in+June/26548312.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced that Christophe Douat, Chief Executive Officer, and Grace Kim, Chief Strategy Officer, U.S. Finance, will participate in the following leading U.S. investor conferences: </p><p> <b>Jefferies Annual NY Biotech Conference</b> </p><ul class="bwlistdisc"> <li> Dates: June 2-4, 2026 </li> <li> Location: New-York </li> <li> Presentation: 9:55 AM ET June 4, 2026 </li> <li> Live webcast and replay: <br /><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fevent.summitcast.com%2Fview%2FNgCqua4VVQjq9ibVWHVWca%2FBz7fjGhGyU3meEzqRduiXr&amp;esheet=54541710&amp;newsitemid=20260526323219&amp;lan=en-US&amp;anchor=https%3A%2F%2Fevent.summitcast.com%2Fview%2FNgCqua4VVQjq9ibVWHVWca%2FBz7fjGhGyU3meEzqRduiXr&amp;index=1&amp;md5=312723785633f98a004023774cc7e0d4" shape="rect">https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/Bz7fjGhGyU3meEzqRduiXr</a> </li> </ul><p> <b>Evercore Summer Symposium</b> </p><ul class="bwlistdisc"> <li> Dates: June 22-24, 2026 </li> <li> Location: Newport, Rhode Island </li> </ul><p> To schedule a meeting, please contact the conference organizers or reach out directly to Medincell. </p><p> <b>About Medincell</b> </p><p> Medincell is a clinical- and commercial-stage biopharmaceutical http://www.streetinsider.com/Press+Releases/Medincell+to+Participate+in+Jefferies+and+Evercore+Investor+Conferences+in+the+U.S.+in+June/26548312.html Tue, 26 May 2026 12:00:00 -0400 A.26800952 A.27499954 MEDCL O.00401804 O.00711722 O.01384798 http://www.streetinsider.com/Press+Releases/Medincell+to+Participate+in+Jefferies+and+Evercore+Investor+Conferences+in+the+U.S.+in+June/26548312.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced that Christophe Douat, Chief Executive Officer, and Grace Kim, Chief Strategy Officer, U.S. Finance, will participate in the following leading U.S. investor conferences: </p><p> <b>Jefferies Annual NY Biotech Conference</b> </p><ul class="bwlistdisc"> <li> Dates: June 2-4, 2026 </li> <li> Location: New-York </li> <li> Presentation: 9:55 AM ET June 4, 2026 </li> <li> Live webcast and replay: <br /><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fevent.summitcast.com%2Fview%2FNgCqua4VVQjq9ibVWHVWca%2FBz7fjGhGyU3meEzqRduiXr&amp;esheet=54541710&amp;newsitemid=20260526323219&amp;lan=en-US&amp;anchor=https%3A%2F%2Fevent.summitcast.com%2Fview%2FNgCqua4VVQjq9ibVWHVWca%2FBz7fjGhGyU3meEzqRduiXr&amp;index=1&amp;md5=312723785633f98a004023774cc7e0d4" shape="rect">https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/Bz7fjGhGyU3meEzqRduiXr</a> </li> </ul><p> <b>Evercore Summer Symposium</b> </p><ul class="bwlistdisc"> <li> Dates: June 22-24, 2026 </li> <li> Location: Newport, Rhode Island </li> </ul><p> To schedule a meeting, please contact the conference organizers or reach out directly to Medincell. </p><p> <b>About Medincell</b> </p><p> Medincell is a clinical- and commercial-stage biopharmaceutical http://www.streetinsider.com/Press+Releases/Medincell+to+Participate+in+Jefferies+and+Evercore+Investor+Conferences+in+the+U.S.+in+June/26548312.html Tue, 26 May 2026 12:00:00 -0400 A.26800952 A.27499954 MEDCL O.00401804 O.00711722 O.01384798 http://www.streetinsider.com/Press+Releases/Medincell+to+Participate+in+Jefferies+and+Evercore+Investor+Conferences+in+the+U.S.+in+June/26548312.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced that Christophe Douat, Chief Executive Officer, and Grace Kim, Chief Strategy Officer, U.S. Finance, will participate in the following leading U.S. investor conferences: </p><p> <b>Jefferies Annual NY Biotech Conference</b> </p><ul class="bwlistdisc"> <li> Dates: June 2-4, 2026 </li> <li> Location: New-York </li> <li> Presentation: 9:55 AM ET June 4, 2026 </li> <li> Live webcast and replay: <br /><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fevent.summitcast.com%2Fview%2FNgCqua4VVQjq9ibVWHVWca%2FBz7fjGhGyU3meEzqRduiXr&amp;esheet=54541710&amp;newsitemid=20260526323219&amp;lan=en-US&amp;anchor=https%3A%2F%2Fevent.summitcast.com%2Fview%2FNgCqua4VVQjq9ibVWHVWca%2FBz7fjGhGyU3meEzqRduiXr&amp;index=1&amp;md5=312723785633f98a004023774cc7e0d4" shape="rect">https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/Bz7fjGhGyU3meEzqRduiXr</a> </li> </ul><p> <b>Evercore Summer Symposium</b> </p><ul class="bwlistdisc"> <li> Dates: June 22-24, 2026 </li> <li> Location: Newport, Rhode Island </li> </ul><p> To schedule a meeting, please contact the conference organizers or reach out directly to Medincell. </p><p> <b>About Medincell</b> </p><p> Medincell is a clinical- and commercial-stage biopharmaceutical http://www.streetinsider.com/Press+Releases/Medincell+to+Participate+in+Jefferies+and+Evercore+Investor+Conferences+in+the+U.S.+in+June/26548312.html Tue, 26 May 2026 12:00:00 -0400 A.26800952 A.27499954 MEDCL O.00401804 O.00711722 O.01384798 http://www.streetinsider.com/Press+Releases/Medincell+to+Participate+in+Jefferies+and+Evercore+Investor+Conferences+in+the+U.S.+in+June/26548312.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced that Christophe Douat, Chief Executive Officer, and Grace Kim, Chief Strategy Officer, U.S. Finance, will participate in the following leading U.S. investor conferences: </p><p> <b>Jefferies Annual NY Biotech Conference</b> </p><ul class="bwlistdisc"> <li> Dates: June 2-4, 2026 </li> <li> Location: New-York </li> <li> Presentation: 9:55 AM ET June 4, 2026 </li> <li> Live webcast and replay: <br /><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fevent.summitcast.com%2Fview%2FNgCqua4VVQjq9ibVWHVWca%2FBz7fjGhGyU3meEzqRduiXr&amp;esheet=54541710&amp;newsitemid=20260526323219&amp;lan=en-US&amp;anchor=https%3A%2F%2Fevent.summitcast.com%2Fview%2FNgCqua4VVQjq9ibVWHVWca%2FBz7fjGhGyU3meEzqRduiXr&amp;index=1&amp;md5=312723785633f98a004023774cc7e0d4" shape="rect">https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/Bz7fjGhGyU3meEzqRduiXr</a> </li> </ul><p> <b>Evercore Summer Symposium</b> </p><ul class="bwlistdisc"> <li> Dates: June 22-24, 2026 </li> <li> Location: Newport, Rhode Island </li> </ul><p> To schedule a meeting, please contact the conference organizers or reach out directly to Medincell. </p><p> <b>About Medincell</b> </p><p> Medincell is a clinical- and commercial-stage biopharmaceutical http://www.streetinsider.com/Press+Releases/Medincell+to+Participate+in+Jefferies+and+Evercore+Investor+Conferences+in+the+U.S.+in+June/26548312.html Tue, 26 May 2026 12:00:00 -0400 A.26800952 A.27499954 MEDCL O.00401804 O.00711722 O.01384798 http://www.streetinsider.com/Business+Wire/Medincell+to+Participate+in+Jefferies+and+Evercore+Investor+Conferences+in+the+U.S.+in+June/26548312.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced that Christophe Douat, Chief Executive Officer, and Grace Kim, Chief Strategy Officer, U.S. Finance, will participate in the following leading U.S. investor conferences: </p><p> <b>Jefferies Annual NY Biotech Conference</b> </p><ul class="bwlistdisc"> <li> Dates: June 2-4, 2026 </li> <li> Location: New-York </li> <li> Presentation: 9:55 AM ET June 4, 2026 </li> <li> Live webcast and replay: <br /><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fevent.summitcast.com%2Fview%2FNgCqua4VVQjq9ibVWHVWca%2FBz7fjGhGyU3meEzqRduiXr&amp;esheet=54541710&amp;newsitemid=20260526323219&amp;lan=en-US&amp;anchor=https%3A%2F%2Fevent.summitcast.com%2Fview%2FNgCqua4VVQjq9ibVWHVWca%2FBz7fjGhGyU3meEzqRduiXr&amp;index=1&amp;md5=312723785633f98a004023774cc7e0d4" shape="rect">https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/Bz7fjGhGyU3meEzqRduiXr</a> </li> </ul><p> <b>Evercore Summer Symposium</b> </p><ul class="bwlistdisc"> <li> Dates: June 22-24, 2026 </li> <li> Location: Newport, Rhode Island </li> </ul><p> To schedule a meeting, please contact the conference organizers or reach out directly to Medincell. </p><p> <b>About Medincell</b> </p><p> Medincell is a clinical- and commercial-stage biopharmaceutical http://www.streetinsider.com/Business+Wire/Medincell+to+Participate+in+Jefferies+and+Evercore+Investor+Conferences+in+the+U.S.+in+June/26548312.html Tue, 26 May 2026 12:00:00 -0400 A.26800952 A.27499954 MEDCL O.00401804 O.00711722 O.01384798 http://www.streetinsider.com/Business+Wire/Medincell+to+Participate+in+Jefferies+and+Evercore+Investor+Conferences+in+the+U.S.+in+June/26548312.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced that Christophe Douat, Chief Executive Officer, and Grace Kim, Chief Strategy Officer, U.S. Finance, will participate in the following leading U.S. investor conferences: </p><p> <b>Jefferies Annual NY Biotech Conference</b> </p><ul class="bwlistdisc"> <li> Dates: June 2-4, 2026 </li> <li> Location: New-York </li> <li> Presentation: 9:55 AM ET June 4, 2026 </li> <li> Live webcast and replay: <br /><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fevent.summitcast.com%2Fview%2FNgCqua4VVQjq9ibVWHVWca%2FBz7fjGhGyU3meEzqRduiXr&amp;esheet=54541710&amp;newsitemid=20260526323219&amp;lan=en-US&amp;anchor=https%3A%2F%2Fevent.summitcast.com%2Fview%2FNgCqua4VVQjq9ibVWHVWca%2FBz7fjGhGyU3meEzqRduiXr&amp;index=1&amp;md5=312723785633f98a004023774cc7e0d4" shape="rect">https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/Bz7fjGhGyU3meEzqRduiXr</a> </li> </ul><p> <b>Evercore Summer Symposium</b> </p><ul class="bwlistdisc"> <li> Dates: June 22-24, 2026 </li> <li> Location: Newport, Rhode Island </li> </ul><p> To schedule a meeting, please contact the conference organizers or reach out directly to Medincell. </p><p> <b>About Medincell</b> </p><p> Medincell is a clinical- and commercial-stage biopharmaceutical http://www.streetinsider.com/Business+Wire/Medincell+to+Participate+in+Jefferies+and+Evercore+Investor+Conferences+in+the+U.S.+in+June/26548312.html Tue, 26 May 2026 12:00:00 -0400 A.26800952 A.27499954 MEDCL O.00401804 O.00711722 O.01384798 http://www.streetinsider.com/Business+Wire/Medincell+to+Participate+in+Jefferies+and+Evercore+Investor+Conferences+in+the+U.S.+in+June/26548312.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced that Christophe Douat, Chief Executive Officer, and Grace Kim, Chief Strategy Officer, U.S. Finance, will participate in the following leading U.S. investor conferences: </p><p> <b>Jefferies Annual NY Biotech Conference</b> </p><ul class="bwlistdisc"> <li> Dates: June 2-4, 2026 </li> <li> Location: New-York </li> <li> Presentation: 9:55 AM ET June 4, 2026 </li> <li> Live webcast and replay: <br /><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fevent.summitcast.com%2Fview%2FNgCqua4VVQjq9ibVWHVWca%2FBz7fjGhGyU3meEzqRduiXr&amp;esheet=54541710&amp;newsitemid=20260526323219&amp;lan=en-US&amp;anchor=https%3A%2F%2Fevent.summitcast.com%2Fview%2FNgCqua4VVQjq9ibVWHVWca%2FBz7fjGhGyU3meEzqRduiXr&amp;index=1&amp;md5=312723785633f98a004023774cc7e0d4" shape="rect">https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/Bz7fjGhGyU3meEzqRduiXr</a> </li> </ul><p> <b>Evercore Summer Symposium</b> </p><ul class="bwlistdisc"> <li> Dates: June 22-24, 2026 </li> <li> Location: Newport, Rhode Island </li> </ul><p> To schedule a meeting, please contact the conference organizers or reach out directly to Medincell. </p><p> <b>About Medincell</b> </p><p> Medincell is a clinical- and commercial-stage biopharmaceutical http://www.streetinsider.com/Business+Wire/Medincell+to+Participate+in+Jefferies+and+Evercore+Investor+Conferences+in+the+U.S.+in+June/26548312.html Tue, 26 May 2026 12:00:00 -0400 A.26800952 A.27499954 MEDCL O.00401804 O.00711722 O.01384798